May 17CMS’ Final Drug Price Rule Doesn’t Include Price Concessions
The Trump administration on Thursday released a final rule aimed at boosting transparency of drug costs on Medicare Part D, but does not include a proposal to pass on price concessions negotiated by the pharmacy to patients.
May 17‘Immoral, Barbaric’ Denials; Huge Roundup Award; PBM ‘Abuse’
After calling UnitedHealthcare's refusal to cover proton therapy for cancer "immoral and barbaric," a federal judge -- and cancer survivor -- recused himself from a case involving one of those coverage denials.
May 17Judge Rips Insurance Company for ‘Immoral, Barbaric’ Cancer Denials
A federal judge blasted UnitedHealthcare last month for its "immoral and barbaric" denials of treatment for cancer patients. He made the comments in recusing himself from hearing a class-action lawsuit because of his own cancer battle -- and in so doing thrust himself into a heated debate in the oncology world.
May 17Pharma’s Bad Behavior is Causing its Own Problems
The pharmaceutical industry is under fire in the public eye, in Congress and in the courts. And it mostly brought this on itself — through price hikes, allegedly anticompetitive behavior and aggressive opioid marketing.
May 17AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 The FDA granted Breakthrough Therapy designation for this combination therapy, and early submission of the data
May 16Democrats are Putting a Political Pothole in the Way of Bipartisan Drug Pricing Bills
The House will vote tomorrow on a package aimed at lowering prescription drug prices — one of the few health-care issues getting across-the-aisle momentum this year, due to overwhelming public support. But in a move that alienates Republicans, Democrats have tacked on measures reversing some of the Trump administration’s controversial actions on the 2010
COA supports a wide variety of initiatives for community oncology practices, professionals, and patient advocates. We give community
oncologists and hematologists a powerful voice to help drive policymaking, innovation, and reform of the cancer care system.